Login to get immediate access to this content.
LoginESMO Members take the CME test
and receive 1 ESMO - MORA point
Learning objectives
- To increase knowledge on risk assessment and rational application of adjuvant strategies in patients with early luminal HER2- breast cancer
- To provide up to date information on the value of CDK4/6 inhibitors in adjuvant management of these patients as well as highlight ongoing research
- To emphasise the value of multidisciplinary assessment of patients with early breast cancer in the personalised medicine era